Status as of August 2026: The U.S. Office of Research Integrity (ORI) has posted a 2025 case summary finding that Liping Zhang, PhD — a former Assistant Professor of Medicine in the Section of Nephrology at Baylor College of Medicine (BCM) — engaged in research misconduct involving falsified and fabricated western blot and immunofluorescence microscopy images across grant applications and unpublished manuscripts funded by NIH. Zhang did not contest the findings, and a two-year period of federal debarment and PHS advisory-committee exclusion began January 16, 2025.
The ORI finding
According to ORI’s case summary, published on ori.hhs.gov in the 2025 case-summary listing, ORI determined that Liping Zhang, PhD, formerly an Assistant Professor in the Department of Medicine, Section of Nephrology, at Baylor College of Medicine, engaged in research misconduct in research supported by three NIH awards:
- R37 DK037175 (National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK)
- P30 DK079638 (NIDDK)
- P30 CA016672 (National Cancer Institute, NCI)
ORI found that Zhang intentionally and knowingly falsified and fabricated data by manipulating western blot and immunofluorescent microscopy images, using images from unrelated experiments, and reusing and relabeling images “to represent falsely different experimental results.” The finding cites, among other examples, a manipulated western blot image in Figure 1G of a manuscript submitted to EMBO Reports, altered immunofluorescence images across multiple figures, systematically reused and relabeled GAPDH and IGF1R loading-control and probe bands, and duplicated western blot images presented as independent replicate experiments.
The falsified and fabricated material appeared in four grant applications submitted to the Public Health Service (PHS) and three unpublished manuscripts submitted for journal review — two to EMBO Reports and one to Cell Reports. Because the affected manuscripts were not published, there is no associated journal correction or retraction tied to this finding as of this writing.
Administrative actions imposed
Zhang did not contest ORI’s findings within the 30-day period provided under the applicable regulations. As a result, ORI imposed the following administrative actions for a two-year period beginning January 16, 2025:
- Debarment from eligibility for U.S. federal government “covered transactions,” under the federal debarment and suspension regulations that apply across executive-branch agencies.
- Exclusion from any PHS advisory role — Zhang is barred from serving in any advisory capacity to the Public Health Service, including as a member of a PHS advisory committee, board, or peer review committee, for the two-year period.
Notably, this case did not include the supervision-and-certification terms (institutional oversight of a respondent’s PHS-supported research, committee review of manuscripts and progress reports, periodic reporting to ORI) that have appeared in several other 2025-2026 ORI findings — the sanction here is confined to debarment and the PHS advisory exclusion.
What research administration offices should take from this finding
ORI case summaries are terse by design — a paragraph or two of findings and a list of administrative actions — but each one is a real, primary-source data point about how image manipulation gets caught and what it costs a researcher and an institution. A few things in this case are worth an RA office’s or research integrity officer’s (RIO’s) attention specifically:
- Multi-grant, multi-manuscript exposure compounds fast. The findings here span three separate NIH awards from two different institutes (NIDDK and NCI) and three separate manuscript submissions. When image manipulation is systemic rather than a single-figure lapse, it tends to surface across everything a researcher has touched — every grant progress report, every renewal application, every co-authored paper — which is exactly why a credible institutional research-integrity process needs to pull the full body of a respondent’s output once a concern is substantiated, not just the document that triggered the initial inquiry.
- The manipulation techniques are the same recurring set image-forensics reviewers are trained to look for. Reused/relabeled bands, duplicated lanes presented as independent replicates, and altered brightness or cropping on immunofluorescence images are the standard vocabulary of western blot and microscopy falsification — the same pattern documented across dozens of other ORI findings and in the broader image-integrity literature. Institutions running pre-submission image screening (a growing practice at PHS-funded institutions, often using tools built for exactly this kind of duplication/manipulation detection) are checking for precisely these signatures.
- Unpublished work is still within ORI’s jurisdiction. None of the three manuscripts implicated here were ever published — misconduct findings do not require a published, retractable paper. Any PHS-supported research record, including material submitted for review and never accepted, is in scope. RA offices should not treat “it never got published” as a reason a concern doesn’t warrant a formal inquiry.
- Debarment plus PHS advisory exclusion, without supervision, is a real but different outcome mix. ORI’s typical administrative-action menu (see, for comparison, CASRAI’s coverage of the Chen-Yeh Ke case) often layers a period of institutional supervision and certification on top of the PHS advisory exclusion. This case shows debarment and the advisory exclusion can stand alone as the imposed remedy — institutions should not assume every ORI finding produces the same package of terms, and should read each case summary’s specific actions rather than generalizing from a prior case.
- A closed employment relationship does not close ORI’s inquiry. Zhang is identified as a former Assistant Professor at Baylor College of Medicine — the finding and the two-year sanction proceeded regardless of the respondent’s departure from the institution where the alleged misconduct occurred. Institutions should not treat a departure as ending their own reporting obligations or ORI’s review.
Why this matters beyond the individual case
Every ORI case summary is a small, primary-source addition to the evidence base research-integrity officers, compliance staff, and grants administrators use to calibrate institutional policy — what pre-submission review actually catches, what PHS considers debarment-worthy versus supervision-worthy, and how long these sanctions typically run. Tracking these findings as they’re posted, rather than only after a high-profile retraction draws press attention, gives RA offices a fuller and more current picture of enforcement patterns than following retraction announcements alone.
Frequently asked questions
What is ORI and what authority does it have?
The Office of Research Integrity, part of the U.S. Department of Health and Human Services, oversees and reviews allegations of research misconduct in Public Health Service-supported research, primarily research funded by NIH. It reviews institutional misconduct findings and can impose federal administrative actions — including debarment, supervision requirements, and exclusion from PHS advisory roles — independent of any action the researcher’s institution takes.
Does an ORI finding automatically mean a paper gets retracted?
No. ORI findings are about the underlying conduct in PHS-supported research, not about any specific journal’s editorial decision. Where affected material was never published — as with two of the three manuscripts in this case — there is no journal correction or retraction to issue, because there was never a published record to correct. Where affected material was published, a retraction or correction is a separate action taken by the journal, sometimes independently of and sometimes prompted by the ORI case.
What is “debarment” in this context?
Debarment excludes an individual from participating in U.S. federal government “covered transactions” — including receiving federal grants, contracts, and certain other forms of federal financial assistance — for the sanction period. It is one of the more severe tools in ORI’s administrative-action toolkit, distinct from and often paired with narrower measures like supervision requirements or advisory-role exclusions.
Where can I read the primary source?
ORI’s full case summary for this finding is published at ori.hhs.gov/content/case-summary-zhang-liping, listed among ORI’s 2025 case summaries at ori.hhs.gov/case_summary.
